Lumos Diagnostics share price rockets 1,036% in 2 days on FDA news

Investors are sending the Lumos Diagnostics share price through the roof following news from the US Food and Drug Administration.

| More on:
Man pointing at a blue rising share price graph.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Lumos Diagnostics Holdings Ltd (ASX: LDX) share price is going through the roof!

Shares in the ASX healthcare stock closed on Friday trading for 1.1 cents. At the time of writing, shares are swapping hands for 12.5 cents.

Shares gained 564% in Monday trade. And they're up another 71% in morning trade today.

That sees the Lumos Diagnostics up a stellar 1,036% in less than two days of trading!

This comes after Lumos, which develops and sells point-of-care diagnostic (POC) tests, reported it had received clearance from the United States Food and Drug Administration (FDA) for one of its core products.

Here are the highlights.

What's happening with the FDA?

Investors are bidding up the Lumos Diagnostics share price after the company received FDA clearance to market its FebriDx rapid, point-of-care test in the US.

FebriDx can now be marketed in the world's top economy to assist healthcare professionals in diagnosing bacterial acute respiratory infections and differentiating this from non-bacterial etiology in urgent care and emergency situations.

FebriDx is already registered in the United Kingdom, Europe, Canada, the United Arab Emirates, Brazil, Turkey, Pakistan, Singapore, Malaysia and Australia.

Lumos Diagnostics noted FebriDx can help combat the overuse of antibiotics, which is contributing to resistant strains of bacteria. The company said most acute respiratory infections are viral in origin, yet antibiotics are commonly prescribed. Up to 40% of these prescriptions are considered unnecessary.

Commenting on the FDA approval sending the Lumos Diagnostics share price rocketing, CEO Doug Ward said, "We are delighted to finally secure clearance to market our FebriDx rapid, point-of-care test in the US as we continue to believe it has an important role to play in antibiotic stewardship."

Ward added:

With this clearance in hand, we anticipate securing our first commercial orders in the US before the end of calendar year 2023. In the meantime, we are continuing to work with distribution partners and potential licensees, as well as establish our own focused sales effort, as we prepare to launch FebriDx in the US.

How has the Lumos Diagnostics share price performed longer term?

While you won't hear any recent investors complaining following this week's surge, the Lumos Diagnostics share price remains down 17% over the past 12 months.

The ASX healthcare share has gained 160% in 2023.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Guess which ASX 200 healthcare stock is charging higher following FDA update

What is getting investors excited today? Let's find out.

Read more »

Two happy scientists analysing test results.
52-Week Highs

3 ASX All Ords health care shares that reached 52-week peaks today

These health care companies finished the week on a positive note.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

2 ASX healthcare shares rocketing over 16% on Big US news

These companies are making their shareholders smile on Thursday. But why?

Read more »

Shot of a young scientist looking stressed while conducting medical research in a laboratory.
Healthcare Shares

Should you buy CSL shares after recent weakness?

Does the dip present a buying opportunity?

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Sigma shares up 25% in 2 days as Chemist Warehouse merger looks set

The deal continues to create tailwinds for Sigma shares.

Read more »

A young woman holds her hand to her mouth in surprise as she reads something on her laptop.
Healthcare Shares

500 million reasons why ResMed shares are charging higher today

This growing company has big plans and is forecasting strong growth through to the end of the decade.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

'Exciting prospect': 2 ASX pharmaceutical shares to keep a close eye on

These companies have developed new drugs to treat vision loss and erectile dysfunction.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Guess which ASX 200 healthcare stock is up 12% on big Chemist Warehouse news

Investors appear to believe this news could be a sign that the deal will go ahead.

Read more »